Navigation Links
Moussa B.H. Youdim wins the 2010 ECNP Lifetime Achievement Award
Date:9/2/2010

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Moussa B. H. Youdim as the recipient of the 2010 ECNP Lifetime Achievement Award in recognition of his innovative and lasting contribution to the area of neurodegenerative diseases and neuropsychiatric drug development. The ECNP Lifetime Achievement Award is presented biennially and recognises significant and lasting impact on the field of neuropsychopharmacology. The award is accompanied by a prize of 20,000.

Moussa B. H. Youdim, born in 1940 in Teheran, is Finkelstein Professor of Life Sciences and at Rappaport Faculty of Medicine at the Technion-Israel Institute of Technology, Haifa, Israel. He is also founder and Director of the Eve Topf and U.S. National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Teaching, an independent extension of the Department of Pharmacology dedicated to advancing the understanding of neuropsychiatric disorders.

"With regard to current treatment standards based on symptom control, innovative neuroprotective therapies are needed in the common neurodegenerative disorders," he emphasised on the occasion of the 23rd ECNP Congress in Amsterdam, the Netherlands. Moussa Youdim has gained a worldwide reputation for his work in addressing this need in Parkinson's disease and Alzheimer's disease over nearly 50 years of highly productive activity.

He is especially known for his key role in establishing the importance of the monoamine oxidase enzymes, which are central to the metabolism of neurotransmitters such as dopamine, noradrenaline and serotonin, and the connection between these enzymes and abnormal brain iron metabolism. He has also pursued this research into the clinic, with the development of novel treatments for neurodegenerative diseases. "A current challenge for drug discovery designed for complex brain disorders such as Parkinson's or Alzheimer's disease is to look for multimodal drugs with a disease modifying effect," said Youdim.

Presenting the award at the 23rd ECNP Congress in Amsterdam, the chairman of the ECNP Award Jury 2010, Tomas Hkfelt of the Karolinska Institute in Stockholm, highlighted Youdim's scientific discoveries and their public health implications. "Demographic changes in Europe are making Parkinson's and Alzheimer's an increasing public health concern. Moussa Youdim's contribution to our understanding and better treatment of these conditions has been lasting and significant. We congratulate him on this well-deserved award."


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
431-405-5734
European College of Neuropsychopharmacology
Source:Eurekalert

Related biology news :

1. Study shows genes role in developing and maintaining cells key for a lifetime of memories
2. University of Washington professors lifetime efforts receive international recognition
3. Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award
4. Dian Donnai receives lifetime award in genetics from March of Dimes
5. Maverick green economist gets lifetime achievement award
6. Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life
7. Roberta A. Pagon receives lifetime award in genetics from March of Dimes
8. Carnegies Donald Brown receives lifetime achievement award from Society for Developmental Biology
9. A low dose of caffeine when pregnant may damage the heart of offspring for a lifetime
10. IOF Medal of Achievement for outstanding scientific contributions awarded to John A. Kanis
11. To close achievement gap, US must address major health risks for urban minority youth, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
(Date:11/14/2016)... 14, 2016  Based on its recent ... & Sullivan recognizes FST Biometrics with the ... Visionary Innovation Leadership. FST Biometrics emerged as ... market by pioneering In Motion Identification (IMID) ... seamless, and non-invasive verification. This patented solution ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 2016 , ... Orthogonal, a Chicago-based medical device software company, ... 510(k) clearance for their flagship medical device, SimplECG. , With this FDA approval, ... rely on cloth-based nanosensors. While other companies have attempted to focus on wearable ...
(Date:12/2/2016)... a world leader in rapid infectious disease tests, introduced the Company,s newest product, the ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited by the ... INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Fla. , Nov. 30, 2016 Biotest ... products, is pleased to announce the addition of its ... Kearney, Nebraska . The 15,200 square ... on November 29th, 2016 and brings the total number ... Ileana Carlisle , BPC,s Chief Executive Officer ...
(Date:11/30/2016)... , 30. November 2016   ... hat heute die Unterzeichnung einer Reihe von ... zufolge wird Evotec AG Screeningleistungen für Mercks ... bereitstellen. Der Zugriff auf diese Bibliotheken in ... eröffnet einen schnelleren Weg zur Ermittlung und ...
Breaking Biology Technology: